Effects of Human Growth Hormone Administration on Serum Somatomedins, Somatomedin Carrier Proteins, and Growth Rates in Children with Growth Hormone Deficiency*
- 1 July 1982
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 55 (1), 49-55
- https://doi.org/10.1210/jcem-55-1-49
Abstract
We have determined the growth rates and serum somatomedin (Sm) and Sm carrier protein (CP) levels in 30 children with GH deficiency and short stature before and up to 3 yr of GH therapy. Initially, the mean (±SEM) bone age (BA) of this group (6.9 ± 0.5 yr) was significantly (Pvs. 1.61 ± 0.12 μg/ml), IGF-I (0.09 ± 0.02 vs. 0.44 ± 0.04/ig/ml), and CP (123 ± 18.8 vs. 366 ± 28.2 μg/ml). Both total IGF and IGF-I were inversely related to the degree of growth retardation, expressed as the ratio of BA to CA. Serum Sm increased in 19 of 21 subjects after short term (up to 18 h) GH administration (0.1 U/kg), but the magnitude of response was not a useful predictor of the Sm response to long term therapy. All subjects exhibited marked increases in growth rate during long term GH therapy (0.1 U/kg, three times weekly), with a mean peak of 11.0 ±0.5 cm/yr during the first 6 months, and 8.4 0.5 cm/yr for the entire period of treatment. Serum total IGF increased from a basal level of 0.31 ± 0.03/μg/ml to a mean of 0.43 ± 0.04/μg/ml (P125I]IGF-I specifically bound to the major chromatographic peaks of serum binding activity in vitro also remained low. However, the quantity of labeled IGF-I bound to the approximately 150,000 molecular weight species increased to normal in response to GH, while that bound to the approximately 60,000 molecular weight form remained unchanged or was even slightly diminished. These studies demonstrate that quantitative relationships exist between GH-induced increments in serum Sm levels and resultant increases in growth rates in GH-deficient children. The data also suggest that other Sms beside IGF-I may be partially GH dependent.Keywords
This publication has 17 references indexed in Scilit:
- Purification of somatomedin-C from human plasma: chemical and biological properties, partial sequence analysis, and relationship to other somatomedinsBiochemistry, 1980
- Role of the Liver in Regulating Somatomedin Activity: Hormonal Effects on the Synthesis and Release of Insulin-Like Growth Factor and Its Carrier Protein by the Isolated Perfused Rat Liver*Endocrinology, 1979
- GROWTH FAILURE WITH NORMAL SERUM RIA-GH AND LOW SOMATOMEDIN ACTIVITY: SOMATOMEDIN RESTORATION AND GROWTH ACCELERATION AFTER EXOGENOUS GHJournal of Clinical Endocrinology & Metabolism, 1978
- Insulin‐Like Growth Factors I and II: Some Biological Actions and Receptor Binding Characteristics of Two Purified Constituents of Nonsuppressible Insulin‐Like Activity of Human SerumEuropean Journal of Biochemistry, 1978
- The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin.Journal of Biological Chemistry, 1978
- Nonsuppressible Insulin-Like Activity (NSILA). I. Development of New Sensitive Competitive Protein-Binding Assay for Determination of Serum Levels*Journal of Clinical Endocrinology & Metabolism, 1978
- Estimation of Somatomedin-C Levels in Normals and Patients with Pituitary Disease by RadioimmunoassayJCI Insight, 1977
- Determination of Nonsuppressible Insulin-Like Activity in Human Serum by a Sensitive Protein-Binding AssayClinical Chemistry, 1977
- Serum somatomedin-C in hypopituitarism and in other disorders of growthThe Journal of Pediatrics, 1977
- Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I.Archives of Disease in Childhood, 1966